Display options
Cite
Hsieh CP, Hsieh MJ, Wu CF, et al. Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection. J Thorac Dis. 2016;8(7):1477-86doi: 10.21037/jtd.2016.05.57.
Hsieh, C. P., Hsieh, M. J., Wu, C. F., Fu, J. Y., Liu, Y. H., Wu, Y. C., Yang, C. T., & Wu, C. Y. (2016). Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection. Journal of thoracic disease, 8(7), 1477-86. https://doi.org/10.21037/jtd.2016.05.57
Hsieh, Chen-Ping, et al. "Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection." Journal of thoracic disease vol. 8,7 (2016): 1477-86. doi: https://doi.org/10.21037/jtd.2016.05.57
Hsieh CP, Hsieh MJ, Wu CF, Fu JY, Liu YH, Wu YC, Yang CT, Wu CY. Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection. J Thorac Dis. 2016 Jul;8(7):1477-86. doi: 10.21037/jtd.2016.05.57. PMID: 27499934; PMCID: PMC4958790.
Copy Download .nbib Format: NLM
Share it on

J Thorac Dis. 2016 Jul;8(7):1477-86. doi: 10.21037/jtd.2016.05.57.

Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection.

Journal of thoracic disease

Chen-Ping Hsieh, Ming-Ju Hsieh, Ching-Feng Wu, Jui-Ying Fu, Yun-Hen Liu, Yi-Cheng Wu, Cheng-Ta Yang, Ching-Yang Wu

Affiliations

  1. Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch; Chang Gung University, Taoyuan, Taiwan ;
  2. Division of Chest and Critical Care, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan Branch; Chang Gung University, Taoyuan, Taiwan.

PMID: 27499934 PMCID: PMC4958790 DOI: 10.21037/jtd.2016.05.57

Abstract

BACKGROUND: Lung cancer is the leading cause of cancer deaths in the world, and more and more treatment modalities have been introduced in order to improve patients' survival. For patients with advanced non-small cell lung cancer (NSCLC), survival prognosis is poor and multimodality neoadjuvant therapies are given to improve patients' survival. However, the possibility of occult metastases may lead to discrepancy between clinical and pathologic staging and underestimation of the disease severity. This discrepancy could be the reason for poor survival prediction reported by previous studies which conducted their analysis from the point of view of clinical stage. The aim of this study was to analyze the relationship between clinico-pathologic factors and survival from the pathologic point of view and to try to identify survival prognostic factors.

METHODS: From January 2005 to June 2011, 88 patients received neoadjuvant therapy because of initial locally advanced disease, followed by anatomic resection and mediastinal lymph node (LN) dissection. All their clinico-pathologic data were collected from a retrospective review of the medical records and subjected to further analysis.

RESULTS: We found that total metastatic LN ratio (P=0.01) and tumor size (P=0.02) were predictive factors for disease free survival (DFS). We used these two prognostic factors to stratify all patients into four groups. Group 4 (tumor size ≤5, total metastatic LN ratio ≤0.065) had the best DFS curve, while the DFS curve progressively deteriorated across group 3 (tumor size ≤5, total metastatic LN ratio >0.065), group 2 (tumor size >5, total metastatic LN ratio ≤0.065) and group 1 (tumor size >5, total metastatic LN ratio >0.065). However, no definitive prognostic factor could be identified in this study.

CONCLUSIONS: In conclusion, tumor size greater than 5 cm and total metastatic LN ratio greater than 0.065 could predict the DFS of patients with advanced NSCLC after multimodality therapies followed by surgical resection. Tumor size plays a more important role than total metastatic LN ratio in DFS. Moreover, patients identified with these factors need active post-operation surveillance and additional aggressive adjuvant therapies.

Keywords: Neoadjuvant therapy; lung cancer; prognostic factor

References

  1. J Thorac Oncol. 2010 Jan;5(1):49-55 - PubMed
  2. Minerva Chir. 2011 Dec;66(6):509-16 - PubMed
  3. Clin Lung Cancer. 2013 Sep;14(5):488-94 - PubMed
  4. Ann Thorac Surg. 2004 Jan;77(1):254-9; discussion 259 - PubMed
  5. World J Surg. 2012 May;36(5):1199-205 - PubMed
  6. Ann Surg Oncol. 2012 Jan;19(1):89-93 - PubMed
  7. Cancer Chemother Pharmacol. 2015 Jan;75(1):77-85 - PubMed
  8. Lung Cancer. 2009 Jun;64(3):301-7 - PubMed
  9. Lung Cancer. 2008 Jun;60(3):393-400 - PubMed
  10. J Bras Pneumol. 2007 Nov-Dec;33(6):647-54 - PubMed
  11. Chest. 2013 Oct;144(4):1253-60 - PubMed
  12. Am J Transl Res. 2014 Oct 11;6(5):593-603 - PubMed
  13. Lancet Oncol. 2015 Apr;16(4):395-405 - PubMed
  14. Eur J Cardiothorac Surg. 2009 Oct;36(4):741-6 - PubMed
  15. Ann Surg Oncol. 2014 Jun;21(6):2083-90 - PubMed
  16. Ann Thorac Surg. 2012 May;93(5):1614-9; discussion 1619-20 - PubMed
  17. J Thorac Oncol. 2012 May;7(5):825-32 - PubMed
  18. J Thorac Oncol. 2013 Feb;8(2):222-8 - PubMed
  19. Thorac Surg Clin. 2008 Nov;18(4):403-15 - PubMed
  20. Transl Lung Cancer Res. 2015 Feb;4(1):82-93 - PubMed
  21. Lung Cancer. 2005 Nov;50(2):227-34 - PubMed
  22. Lung Cancer. 2004 Feb;43(2):151-7 - PubMed
  23. Thorax. 2011 Apr;66(4):287-93 - PubMed
  24. Ann Oncol. 2006 May;17 Suppl 5:v55-61 - PubMed
  25. Chest. 1997 Jun;111(6):1710-7 - PubMed
  26. Eur J Cardiothorac Surg. 2011 Sep;40(3):664-70 - PubMed
  27. Ann Thorac Surg. 2004 Dec;78(6):1903-9; discussion 1909 - PubMed
  28. Ann Thorac Surg. 1999 Oct;68(4):1171-6 - PubMed
  29. J Clin Oncol. 2003 Jul 15;21(14 ):2651-7 - PubMed
  30. Eur J Nucl Med Mol Imaging. 2006 Jul;33 Suppl 1:11-5 - PubMed
  31. Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):263-9 - PubMed
  32. Ann Oncol. 2010 Oct;21 Suppl 7:vii230-3 - PubMed
  33. PLoS One. 2013 Oct 25;8(10 ):e78552 - PubMed
  34. Ann Surg Oncol. 2013 Oct;20(11):3648-54 - PubMed
  35. J Surg Oncol. 2010 May 1;101(6):486-94 - PubMed
  36. Ann Thorac Surg. 1992 Sep;54(3):460-5; discussion 466 - PubMed
  37. Rev Assoc Med Bras (1992). 2010 Mar-Apr;56(2):237-41 - PubMed

Publication Types